Shimizu, T., Shimizu, T., Powderly, J., Razak, A. A., LoRusso, P., Miller, K. D., . . . Tolcher, A. Corrigendum: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP: TGF-ß1 complex, as monotherapy and in combination with the anti–PD-1 antibody budigalimab in patients with advanced solid tumors. Frontiers Media S.A.
Chicago Style (17th ed.) CitationShimizu, Toshio, et al. Corrigendum: First-in-human Phase 1 Dose-escalation Results with Livmoniplimab, an Antibody Targeting the GARP: TGF-ß1 Complex, as Monotherapy and in Combination with the Anti–PD-1 Antibody Budigalimab in Patients with Advanced Solid Tumors. Frontiers Media S.A.
MLA (9th ed.) CitationShimizu, Toshio, et al. Corrigendum: First-in-human Phase 1 Dose-escalation Results with Livmoniplimab, an Antibody Targeting the GARP: TGF-ß1 Complex, as Monotherapy and in Combination with the Anti–PD-1 Antibody Budigalimab in Patients with Advanced Solid Tumors. Frontiers Media S.A.